OBJECTIVE: The relative bioavailability of two highly concentrated (12 IU/mL) formulations
of biosynthetic human growth hormone (GH) administered subcutaneously was compared …

Background: GH treatment currently requires daily sc injections, resulting in suboptimal
compliance. A GH regimen with fewer injections may offer patients and caregivers a less …

Background/Aims: MOD-4023 is a long-acting human growth hormone (hGH) in clinical trials
for the treatment of growth hormone deficiency (GHD). A key goal is maintenance of serum …

Objective Adult GH replacement is currently given by daily subcutaneous (sc) injections.
Recently, sustained‐release (SR) preparations of GH have been developed, the …

The pharmacokinetic parameters of MHGH 22K, such as the mean values of t 1 2 (9.30,
16.8, 22.2 vs 25.8 min), MRT (11.6, 21.7, 26.7 vs 37.9 min) and V ss (166, 218, 342 vs 556 …

A novel recombinant human growth hormone (rhGH) fusion protein (VRS-317) was
designed to minimize receptor-mediated clearance through a reduction in receptor binding …

The availability of recombinant human growth hormone (GH) has broadened its range of
clinical applications. Approved indications for GH therapy include treatment of growth …

Context: Daily injections are required for growth hormone (GH) replacement therapy, which
may cause low compliance as a result of inconvenience and distress in patients. Objective …

Aims To investigate the absorption profile and estimate the bioavailability of three doses of
recombinant human growth hormone (rhGH) smaller than 2 IU in females with GH deficiency …

Recombinant human growth hormone (rhGH) therapy for short stature must be administered
as a daily injection because of its poor bioavailability and short half-life. In the present study …